Study on the duration of action of ensidipine

Enasidenib, trade name: Idhifa, is a drug that targets IDH2 (isocitrate dehydrogenase2) mutated acute myeloid leukemia (AML). It inhibits the activity of IDH2 enzyme and reduces the production of abnormal metabolite 2-HG, thereby restoring normal cell differentiation and inhibiting the growth of leukemia cells.

Ensidipine is rapidly absorbed after oral administration, reaching peak plasma concentration, and then undergoes metabolism by cytochromeP450 enzymes in the liver, and is finally excreted through urine and feces. The terminal half-life of ensidipine is 7.9 days. This feature allows once-daily dosing to maintain effective blood concentrations and ensure sustained drug action.

Although the half-life of ensidipine provides information about the rate of elimination of the drug from the body, current research and clinical trials have not provided clear conclusions regarding its exact duration of action. Each patient's response to ensidipine may vary based on factors such as disease severity, individual differences, and concomitant medications. Therefore, duration of action is a relatively complex and individualized issue.

In clinical practice, doctors usually develop individualized treatment plans based on the patient's specific conditions (such as disease status, treatment response, etc.), and closely monitor the patient's treatment effects and adverse reactions. This helps ensure that ensidipine is able to maximize its therapeutic effect in patients while minimizing potential side effects.

For patients being treated with ensidipine, it is critical to regularly monitor the effectiveness of treatment. This usually involves blood tests to assess the load of AML cells and response to treatment. Based on the monitoring results, your doctor may decide to continue using ensidipine, adjust the dose, or take other treatment measures.

In addition, patients should pay close attention to their physical condition and any discomfort reactions while using ensidipine, and communicate with their doctors in a timely manner. Through close cooperation with doctors and the implementation of individualized treatment plans, patients can achieve the best treatment results, prolong survival and improve quality of life as much as possible.

References:

https://go.drugbank.com/drugs/DB13874